Pfizer June 15th Short Interest Update

Pfizer (NYSE:PFE), A increase of 336,033 shares or 0.6% was observed in the short interest of Pfizer The interest on June 15,2016 came in at 55,944,798 shares and as per the average daily trading of 24,816,130 shares, the days to cover are 2. The increased interest is 0.9% of the floated shares. The data of May 31,2016 put the interest at 55,608,765 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Pfizer (NYSE:PFE): The stock opened at $33.80 on Friday but the bulls could not build on the opening and the stock topped out at $34.45 for the day. The stock traded down to $33.74 during the day, due to lack of any buying support eventually closed down at $33.97 with a loss of -1.79% for the day. The stock had closed at $34.59 on the previous day. The total traded volume was 44,000,223 shares.

The company shares have rallied 1.13% from its 1 Year high price. On Jul 31, 2015, the shares registered one year high at $36.46 and the one year low was seen on Feb 8, 2016. The 50-Day Moving Average price is $34.26 and the 200 Day Moving Average price is recorded at $31.90.

Pfizer (NYSE:PFE) has tumbled 0.73% during the past week and has dropped 1.85% in the last 4 week period. In the past week, the company has outperformed the S&P 500 by 0.92% and the outperformance has advanced to 1.12% for the last 4 weeks period.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *